IgAN is a serious, immune-mediated, progressive disease with an average age at diagnosis of ~35 years old, leading to severe impact on quality of life2
BAFF = B-cell activating factor; APRIL = A proliferation-inducing ligand; TACI = transmembrane activator and calcium-modulator and cyclophilin ligand interactor.
1Cheung CK, et al. Front Nephrol 2023; 2Dillon SR, et al. Arthritis Res Ther 2010; 3Vera data on file; 4Willen D, et al. Eur J Drug Metab Pharmacokinet 2020; 5Gordon C, et al. Rheumatol Adv Pract 2019 and data on file; 6Lafayette R, et al. Kidney Int 2024; 7 Barratt J, et al. JASN 2024.
IgAN, also known as Berger’s disease, is a B-cell mediated kidney disease driven by the deposition of abnormal immune complexes that accumulate in the kidneys, causing inflammatory tissue damage and kidney failure1
IgAN is a serious, immune-mediated, progressive disease with an average age at diagnosis of ~35 years old, leading to severe impact on quality of life2
At least 50% of IgAN patients progress to end-stage kidney disease within 20 years, requiring dialysis or kidney transplant3,4
Despite current standard of care with ACEi/ARBs and CKD supportive care,5 kidney function may steadily decline6
There is a high unmet medical need for safe and effective new disease-modifying treatments for IgAN that target the upstream source of disease7
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CKD = chronic kidney disease.
1Wyatt RJ, et al. N Engl J Med 2013; 2Jarrick S, et al. J Am Soc Nephrol 2019; 3Kwon CS, et al. J Health Econ Outcomes Res 2021; 4Pitcher D, et al. Clin J Am Soc Nephrol 2023; 5KDIGO 2021; 6Cheung CK, et al. J Clin Med 2021; 7Huang X, Xu G. Front Pharmacol 2021.
Multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
For more information, contact MEDINFO@VERATX.COM
Multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety and efficacy of atacicept 150 mg in adults with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
Learn more at clinicaltrials.gov.
Visit the Vera Therapeutics Medical Affairs website for publications, congress presentations, and medical information resources for U.S. healthcare professionals.
Expanded Access Policy
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases that improve patients’ lives. We work urgently to advance therapies that will improve the standard of care.
The goal of our clinical study programs is to obtain clinical data on investigational therapies that is required by the U.S. Food and Drug Administration (FDA) and other regulatory authorities for review and approval of marketing applications.
We believe that focusing on clinical studies is the most appropriate way to achieve this goal; therefore, we do not currently offer access to investigational therapies outside of clinical studies and, at this time, we have no Expanded Access Program (sometimes referred to as “compassionate use” or “pre-approval access”).
If you have additional questions regarding Vera’s clinical trial program, please speak with your healthcare provider or contact: clinicaltrials@veratx.com.